- Home
- AVIR vs NAUT Comparison
AVIR vs NAUT Comparison
Compare AVIR & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | NAUT |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.9M | 383.5M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVIR | NAUT |
|---|---|---|
| Price | $5.33 | $3.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | ★ 581.8K | 319.5K |
| Earning Date | 03-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 16.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $992.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $0.62 |
| 52 Week High | $6.45 | $4.31 |
Technical Indicators
Market Signals| Indicator | AVIR | NAUT |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 71.97 |
| Support Level | $3.33 | $1.82 |
| Resistance Level | $6.45 | N/A |
| Average True Range (ATR) | 0.30 | 0.33 |
| MACD | -0.13 | 0.14 |
| Stochastic Oscillator | 21.79 | 73.09 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.